A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Trial Profile

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Tisagenlecleucel (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms JULIET
  • Sponsors Novartis
  • Most Recent Events

    • 03 Apr 2018 Planned End Date changed from 1 Jan 2020 to 20 Feb 2023.
    • 03 Apr 2018 Planned primary completion date changed from 1 Jan 2024 to 20 Feb 2023.
    • 14 Mar 2018 Planned End Date changed from 1 Jan 2024 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top